Drugs / KQ-2002 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06445803 | May 2024 → Oct 2026 expected | B-cell acute lymphoblastic leukemia | Rong Tao | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KQ-2002 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06445803 ↗ |
| Known as | KQ-2002 | “A Preliminary Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetic Profile of KQ-2002 (CD19/CD22 CAR-T) in Adults With Recurrent or Refractory...” NCT06445803 ↗ |
| Modality | Cell therapy | “anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site” NCT06445803 ↗ |
| Target | CD19 | “anti-CD19 /CD22 CAR T cells” NCT06445803 ↗ |
| Target | CD22 | “anti-CD19 /CD22 CAR T cells” NCT06445803 ↗ |